Metojectpen

Methotrexate, the active ingredient in Metojectpen, is an antimetabolite (folate antagonist) presented as a pre‑filled subcutaneous injection pen for subcutaneous use. It treats rheumatoid arthritis, severe plaque psoriasis, juvenile idiopathic arthritis, and certain malignancies such as acute lymphoblastic leukemia and lymphoma.

GNH USA supplies Metojectpen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, oncology centres and clinics worldwide. The company ensures consistent quality and regulatory compliance across a broad range of therapeutic areas, with reliable logistics and support for clinical programs.

Methotrexate is used as a disease‑modifying antirheumatic drug (DMARD) and antineoplastic agent to manage inflammatory and malignant conditions. - Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Severe plaque psoriasis: decreases skin lesions and plaque formation. - Juvenile idiopathic arthritis: controls disease activity and improves joint function. - Acute lymphoblastic leukemia: interferes with malignant cell proliferation. - Lymphoma: inhibits growth of malignant lymphoid cells.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting. - Fatigue or weakness. - Mouth ulcers or stomatitis. - Elevated liver enzymes.

Serious or Rare Side Effects: - Severe liver toxicity, including hepatitis or fibrosis. - Pulmonary toxicity such as interstitial pneumonitis. - Bone marrow suppression leading to severe infection, anemia or thrombocytopenia.

Before initiating therapy, clinicians should assess baseline organ function and counsel patients on potential risks. - Monitor liver function: perform regular hepatic enzyme tests. - Monitor blood counts: check complete blood count frequently. - Avoid use in pregnancy: methotrexate is teratogenic (Category X). - Use caution in renal impairment: adjust dosing as needed. - Counsel on infection signs: advise immediate medical attention for fever or unexplained illness. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several medicines that can alter its safety or efficacy.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Trimethoprim‑sulfamethoxazole: heightens risk of bone‑marrow suppression. - Live vaccines: may cause severe infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Azathioprine: additive immunosuppressive effect, monitor blood counts. - Allopurinol: may increase methotrexate levels, watch for toxicity. - Phenytoin: can reduce methotrexate clearance, adjust monitoring accordingly.